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• Views and interpretations are those of the 
speaker 
– do not necessary reflect those of state partners or 
federal funding agencies (NIDA/CDC/SAMHSA/ARC). 
The U.S. Opioid Epidemic Continues
Hedegaard et al. 2020
Opioid Epidemic
in Rural & Urban Communities
CDC, 2017
High Rate of Increase in Opioid-related Mortality 
in Rural Counties, 1999-2016
CDC, 2017, Rigg et al., 2018
HCV Incidence among persons aged ≤30
Kentucky, Tennessee, Virginia, & West Virginia, 2006–12
Zibbell et al. MMWR 2015







Singer, 1994; Rhodes et al., 2005; Nikolopoulos et al 2015; Perlman & Jordan, 2018.




•Policy and cultural status of 
drug use
•Access to needed services
•CJ activity
•“Big events”
Syndemic Outbreak in Scott County IN, 2014-15
Peters et al. NEJM 2016; Gonzalves & Crawford , Lancet 2018
CDC: 220 Counties Most Vulnerable to 
OUD-related Outbreak of HIV
Van Handel et al. JAIDS 2016; opioid.AMFAR.org
Top 220 Counties
206 (94%) have no SSP
CDC: 220 Counties Most Vulnerable to 
OUD-related Outbreak of HIV
Van Handel et al. JAIDS 2016; opioid.AMFAR.org
Top 220 Counties
NIDA/CDC/SAMHSA/ARC Funded
8 Rural Opioid Initiative (UG3) Sites and GHOST Lab
NIDA RFA:“HIV, HCV and Related 
Comorbidities in Rural Communities 
Affected by Opioid Injection Drug 
Epidemics in the United States: 
Building  Systems for Prevention, 
Treatment & Control “
Syndemic Concerns not theoretical in our region…
• 2105-18: 129 new HIV+ in 
Lowell and Lawrence 




o High rates of homelessness
DISCERNNE: A 2-Phase Study
1. UG3 (2 yrs): 
In 11 rural counties along the I-91/   
CT River corridor in MA, NH, VT: 
• Characterize the epidemiology 
of overdose and injection-
associated infectious disease
• Assess local policy, resource and 
risk environment
2. UH3 (3 yrs): 
field an intervention to address gaps
UG3: Mixed Method Study
• Assess public health data, law, policies and services
• Respondent-driven sample (RDS) survey, 5/18-10/19
– N=589, age 18+, IDU or opioid use in prior 30 days 
– 90-minute quantitative and social network survey
– Toxicology and laboratory testing (HIV, HCV, syphilis)
• Semi-structured interviews
– Stakeholders (n = 31)
• healthcare, harm reduction, addiction tx, public health, law 
enforcement
– Persons who use drugs (PWUDs) (n=22)
Stopka et al., Prev Med 2019
Epidemiologic, Policy and Legal Environment


















Stopka et al., Prev Med 2019
UG3: Mixed Method Study
• Assess public health data, law, policies and services
• Respondent-driven sample (RDS) survey, 5/18-10/19
– N=589, age 18+, IDU or opioid use in prior 30 days 
– 90-minute quantitative and social network survey
– Toxicology and laboratory testing (HIV, HCV, syphilis)
• Semi-structured interviews
– Stakeholders (n = 31)
• healthcare, harm reduction, addiction tx, public health, law 
enforcement
– Persons who use drugs (PWUDs) (n=22)




Male, % 58% 58%
Median age (IQR) 34 (28-42) years 33 (27–41) years
Non-Hispanic white, % 88% 99%
Homeless past 6 mos, % 56%
Shared inj equip % 53% past 30 days 70% ever
Incarcerated, % 29% past 6 mos. 54% past year
Sex for money or drugs 10% past 30 days 9% ever































Ever used "to get high" Current drug of choice
• > 95% had ever used opioid painkillers, heroin, & cocaine/crack


























Most have h/o Addiction Treatment, 


















Ever Past 30 days
• 79% ever treated – counseling most common
• 32% have not had access to MOUD























Addiction Treatment Received in the Past 30 Days
Frequency of Injection



































60% daily or more
• Overall 85% h/o injection
Injection Behavior












PWIDs shared equipment Injected multiple times in one sitting
UG3: Mixed Method Study
• Assess public health data, law, policies and services
• Respondent-driven sample (RDS) survey, 5/18-10/19
– N=589, age 18+, IDU or opioid use in prior 30 days 
– 90-minute quantitative and social network survey
– Toxicology and laboratory testing (HIV, HCV, syphilis)
• Semi-structured interviews
– Stakeholders (n = 31)
• healthcare, harm reduction, addiction tx, public health, law 
enforcement
– Persons who use drugs (PWUDs) (n=22)
Stopka et al., Prev Med 2019
Syringe sharing common
“…if somebody wants to get high and they don’t 
have a needle to use, they’ll pick one up of the 
ground and use it. That’s how desperate they 
are…It could’ve been 500 people…and they’ll still 
pick it up and use it. Because, and, and they 
won’t, and they won’t say oh well, I’ll just sniff it 
this time. That’s not going to happen. They’ll 
hunt it down until they find it.”
-Participant, Keene, NH
Syringe Access












% of participants reporting 










































NH (n=154) VT/MA (n=299)
HIV & Major Bacterial Infections
• 81% previously tested for HIV
– 84% received results
• 7 (1%) reported told they were HIV positive
• 3 have a doctor and take medication
• No new HIV detected
• 31% heard of med to prevent HIV (PrEP)
• 10% had been hospitalized for major bacterial 
infection
HCV Prevalence and Treatment
(n=422 PWID with usable results)
Of the 433 adult PWID, 67% tested positive for HCV antibodies





























GEE Model: Correlates of HCV Serostatus
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
Age (per 10 years)
Non-White race (vs. White)
Homeless in past 6 mo.
Incarcerated in past 6 mo.
Inject at least 1x/day (vs. < daily)
Shared injection equip. in past 30 days











HCV not a strong deterrent to sharing
“Nowadays they just say ‘well what, do you got hep C? I 
got hep C. Well that’s it? Alright. Well I got it too.’ And 
they’ll joke around like ‘well hep C’s got so many 
different strands that well you’ll just get another 
strand. Or I’ll get another strand. Or all three of us. We 
got three new strands!’ It’s like a joke.”

















HCV seropositive Shared Inj. Equip. (past 30 days) Somewhat/strongly agree it's easy
to get clean syringes
%
Windham (n=132) Cheshire (n=117)


















Stigma remains a barrier 
to effective intervention
From a SSP staff person –
“And there’s still like…there’s a real hard core…opposition to treating 
people who use drugs for Hepatitis C.… just like what drug users should and 
shouldn’t have access to or rights to. And that influences policy advocacy 
and acquisition and money, you know?”
From an emergency room doctor –
“And I’ve learned that you can treat Hep C, but if you keep using needles 
you’ll catch it again. So that $100,000 treatment might have to be repeated. 
And I know the state of the Medicaid budget in this state, and I think these 
people are going to be on their own. I don’t think the state can afford it.”
From a police chief in a town that has an SSP –
“Well, I think, um, uh, we do not have a needle exchange program and I 
don’t support it and wouldn’t advocate for it.”
Transportation
“…if you take limited hours and then you take 
limited transportation, you put the two things 
together, you have a serious access problem… 
And sometimes you might have to hang out for 
hours just finding something to do before you 
can make it back to your home. Maybe you are 
going to miss work…”
My god it’s horrible. I literally 
can remember…thinking 
that [this town] was a great 
area to grow up in and raise 
a family. And maybe I was 
just really extra oblivious 
then but, uh, it’s, drugs were 
like scarce. [Using drugs] 
was the exception. Now 
people that don’t do drugs 
are the exception. There’s 
more drugs or people 
using… everywhere. 
(Amanda, 29F)
Pain & Abrupt D/C of 
Prescription Opioids 
Normalization of Drug Use 








I was 12 years old…My 
father gave me a line of 
oxycodone…he just 
broke it out and said 
here, sniff this. And I 
said, uh how? And he 
showed me how he did 
it, and I did it. (Jacob, 
24M)
Transition to heroin
Last year I lost my baby…it was a 
stillborn…before that I lost my best friend’s 
dad who was like a father to me growing up… 
just three weeks ago my mothers’ boyfriend 
shot himself in the head in front of my mom. 
But it’s just a lot of trauma happening 
lately…it’s just a lot of things piling up. Life’s 
pretty unforgiving sometimes. (Matt, 24M)
And then the doctor took them 
away from me and I was in pain. I 
was sick, throwing up… physically 
was sick from it, from not having 
it. And where did I go? I went to 
the streets to find them. And then 
that became too expensive. And 
then I went to heroin.  (Jessica, 
32F)
So they took me in and did surgery 
and they put me on, um oxycontins 60 
milligrams four times a day…And 
that’s why I got addicted. I was on it 
for two or three years, and then finally 
they shut me off…They supposedly 
got a call saying that we were abusing 
meds or selling them or whatever…I 
know like four or five people that… all 
got shut off the same day…I tried to 
find the pill if I had the money. But 
yeah, you couldn’t. .. Yes, so I went to 
the heroin. (Michelle, mid-50s F)
Escalation of use
Themes Related to Opioid 
Use & Transition to Injection
Nolte et al., Submitted DAD.
Summary: Rural NNE Risk Environment
• Area-level deprivation/social capital
• Unemployment, trauma, stigma, distrust, 
provider unwillingness to treat active users for HCV 
• Policy and cultural status of drug use
• Policy climate limits action, normalization of drug use and 
syringe sharing 
• Access to needed services




Significant Population at Risk in Rural NNE
• CDC analysis underestimated risk in NNE
– High rates syringe sharing and HCV
– SSP access limited
• After conferring with local partners
– States have MOUD initiatives in motion
– UH3 focus on HCV treatment and harm 
reduction
UH3 2020-2022
Mobile Tele-HCV Treatment Integrated w/ Syringe Services
1. Examine effectiveness of 
mobile telemedicine 
treatment for HCV 
integrated with syringe 
services
2. Validate the accuracy of dried 
blood spot (DBS) testing for HCV 
viral load as a surveillance 




Mobile tele-HCV care will be associated with:
• HCV treatment initiation
• HCV SVR 12-weeks post treatment
• Reduced syringe sharing
Secondary outcomes 
• HAV and HBV vaccination completion rates
• MOUD initiation
• Health-related quality of life (HRQOL) 
• Substance use
Can HCV Tx ↓ Sharing of 
Injection Equipment?
• 5 studies of impact of HCV tx on injecting behavior
– ↓past month injection drug use 3 of 4 studies
– ↓weekly injection frequency 1 of 2 studies 
– ↓sharing 2 of 3 studies
– All but one from interferon era
• Two Phase 4 DAA studies (n=190)
– At baseline, 62% reported injecting past month
• 47% opioids, 39% stimulants 
• 61% receiving MOUD
• 16% reported sharing injection equipment. 
– Over 2 year f/u, 
• ↓ opioid injection (OR = 0.95; 95% CI, 0.92-0.99) 
• ↓ sharing of injection equipment (OR = 0.87; 95% CI, 0.80-0.94)
• Limited impact on stimulant injection






 Rapid HCV test
 Fibroscan




























 HAV & HBV 
vaccination
Both groups:
 Initial HAV & HBV vaccination
 Harm reduction services
 ACASI












UH3 Intervention Plan: Outcomes
• End-of-treatment (8 or 12 wks)
• Post-treatment follow up (12, 24 & 36 wk later)
– ACASI: HCV Tx initiation, adherence; syringe sharing; 
quality of life; substance use 
– Blood: DBS, virologic response (e.g. SVR12), viral 
genetics
– Ethnography, on-the-spot interviews to assess 
implementation
Summary
• Several rural northern NE counties are at high 
risk for Scott County-like outbreaks — syringe 
sharing and HCV are highly prevalent:
• Mobile van in UH3 to address service gaps
– Access to harm reduction, phlebotomy services
– HCV testing and treatment limited, esp. in NH & VT
• Comprehensive, long-term community-level 
and policy interventions needed to address risk 
and resource environment.
Study Team
University of Massachusetts Medical School-Baystate:
Peter D. Friedmann, MD, MPH, DFASAM, FACP (Multi 
Principal Investigator, Contact)









Tufts University School of Medicine:
Thomas J. Stopka, PhD, MHS (Multi Principal Investigator)
Erin Jacque
The Dartmouth Institute:






Bryan J. Marsh, MD (Co-Investigator)
David de Gijsel, MD, MSc (Co-Investigator)
University of New Hampshire:
Kerry Nolte, PhD, FNP-C (Co-Investigator)




New Hampshire Department of Health and Human 
Services:
Benjamin Chan, MD, MPH
Elizabeth Talbot, MD
Joseph Harding
University of Vermont Medical Center:
Jean Dejace, MD (Co-Investigator)
W. Kemper Alston, MD, MPH
Thank you to…
• The participants for sharing their stories and 
helping us to understand their experiences
• Local harm reduction, opioid use disorder 
treatment and medical care partners
• Dartmouth Institute
• Massachusetts Dept of Public Health
• NH Dept of Health and Human Services
• VT Dept of Health
• Tufts School of Medicine
• UMMS-Baystate
• University of New Hampshire
• UVM School of Medicine 
Epidemiologic, Policy, and Legal Environment
Stopka et al., Prev Med 2019
UG3 Cross-sectional Analysis: 
HCV treatment & Risk Behaviors




No Hx of HCV 
treatment
(n=161), No. (%)
Syringe sharing 12 (46) 88 (55)
Sharing other injection equipment 13 (50) 91 (57)
Backloading 12 (46) 81 (50)
• Among the 187 PWID who reported previously having tested 
positive for HCV:
*risk behaviors and history of HCV treatment were both self-reported
